The Impact of Anti-Amyloid Immunotherapies on Stroke Care

被引：3

作者：

Bilodeau, Philippe A. ^{[1
]}

Dickson, John R. ^{[2
]}

Kozberg, Mariel G. ^{[2
,3
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Neuroimmunol & Neuroinfect Dis, Boston, MA 02114 USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, MassGeneral Inst Neurodegenerat Dis, 114 16th St, Boston, MA 02129 USA

[3] Harvard Med Sch, Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA

来源：

JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 05期

关键词：

anti-amyloid immunotherapy; amyloid-related imaging abnormalities; ARIA-E; ARIA-H; cerebral amyloid angiopathy; ischemic stroke; antithrombotics; thrombolytics; ANGIOPATHY-RELATED INFLAMMATION; ATRIAL APPENDAGE CLOSURE; BETA-RELATED ANGIITIS; CORTICAL SUPERFICIAL SIDEROSIS; 2-PHASE; TRIALS; INTRACEREBRAL HEMORRHAGE; IMAGING ABNORMALITIES; ALZHEIMER-DISEASE; CEREBRAL-HEMORRHAGE; BAPINEUZUMAB;

D O I：

10.3390/jcm13051245

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-amyloid immunotherapies have recently emerged as treatments for Alzheimer's disease. While these therapies have demonstrated efficacy in clearing amyloid-beta and slowing cognitive decline, they have also been associated with amyloid-related imaging abnormalities (ARIA) which include both edema (ARIA-E) and hemorrhage (ARIA-H). Given that ARIA have been associated with significant morbidity in cases of antithrombotic or thrombolytic therapy, an understanding of mechanisms of and risk factors for ARIA is of critical importance for stroke care. We discuss the latest data regarding mechanisms of ARIA, including the role of underlying cerebral amyloid angiopathy, and implications for ischemic stroke prevention and management.

引用

页数：16

共 50 条

[31] Candesartan-the next anti-amyloid drug?
Yasar, Sevil
BRAIN COMMUNICATIONS, 2022, 4 (06)
[32] Following nature's anti-amyloid strategy
Peter T. Lansbury
Nature Biotechnology, 2001, 19 : 112 - 113
[33] Production of Anti-Amyloid β Antibodies in Mice Fed Rice Expressing Amyloid β
Nojima, Jun
Ishii-Katsuno, Rika
Futai, Eugene
Sasagawa, Noboru
Watanabe, Yuichiro
Yoshida, Taiji
Ishiura, Shoichi
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2011, 75 (02) : 396 - 400
[34] Contextualising the benefits and risks of anti-amyloid therapy for patients with Alzheimer disease and their care team
Bhalala, Oneil G.
Thompson, Jane
Watson, Rosie
Yassi, Nawaf
MEDICAL JOURNAL OF AUSTRALIA, 2024, 221 (02) : 78 - 82
[35] Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis
Fedele, Ernesto
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
[36] Anti-amyloid: An antibody to cure Alzheimer's or an attitude
Osborne, Olivia M.
Naranjo, Oandy
Heckmann, Bradlee L.
Dykxhoorn, Derek
Toborek, Michal
ISCIENCE, 2023, 26 (08)
[37] Dementia research in 2023: the year of anti-amyloid immunotherapy
Delrieu, Julien
Andrieu, Sandrine
Vellas, Bruno
LANCET NEUROLOGY, 2024, 23 (01): : 13 - 15
[38] Measurement of Anti-Amyloid β Autoantibodies in Patients with Rheumatoid Arthritis
Sato, Masao
Takemura, Masao
Tani, Tomohisa
Ohashi, Toshiro
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[39] Will anti-amyloid therapies work for Alzheimer's disease?
St George-Hyslop, Peter H.
Morris, John C.
LANCET, 2008, 372 (9634): : 180 - 182
[40] Anti-amyloid treatments: Why we think they are worth it
Schindler, Suzanne E.
Musiek, Erik S.
Morris, John C.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2025, 11 (01)

← 1 2 3 4 5 →